OB/GYN Clinical Alert – September 1, 2014

September 1, 2014

• Do Patients Need Routine Pelvic Exams?

  A review of the published literature finds no value to the routine screening pelvic examination in asymptomatic non-pregnant women.

  Read more

• More Promise from Olaparib in Recurrent Ovarian Cancer: The BRCA Cohort

  Olaparib, a poly (ADP)-ribose polymerase (PARP) inhibitor, demonstrated substantial delay until progression when administered to women as a maintenance therapy with BRCA-mutant recurrent ovarian cancer.

  Read more

• Reduced Fetal Movement, Uterine Arteries, and Stillbirth

  A recent study has shown a link between abnormal uterine artery waveforms in the second trimester and reduced fetal movements later in pregnancy, as well as with stillbirth and small for gestational age.

  Read more

• AMH: Marker of Ovarian Reserve and More

  Serum anti-Mullerian hormone (AMH) has been well-established as an accurate marker of ovarian reserve. It is solely produced in the human ovary by the granulosa cells.

  Read more